WO1996038555A3 - Unc-53 from c. elegans and its uses in testing compounds involved in the control fo cell behaviour and pharmaceutical compositions - Google Patents

Unc-53 from c. elegans and its uses in testing compounds involved in the control fo cell behaviour and pharmaceutical compositions Download PDF

Info

Publication number
WO1996038555A3
WO1996038555A3 PCT/EP1996/002311 EP9602311W WO9638555A3 WO 1996038555 A3 WO1996038555 A3 WO 1996038555A3 EP 9602311 W EP9602311 W EP 9602311W WO 9638555 A3 WO9638555 A3 WO 9638555A3
Authority
WO
WIPO (PCT)
Prior art keywords
unc
protein
elegans
pharmaceutical compositions
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/002311
Other languages
French (fr)
Other versions
WO1996038555A2 (en
Inventor
Thierry Bogaert
Eve Stringham
Joel Vandekerckhove
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE69636388T priority Critical patent/DE69636388D1/en
Priority to EP96918643A priority patent/EP0832222B1/en
Priority to AU61234/96A priority patent/AU6123496A/en
Publication of WO1996038555A2 publication Critical patent/WO1996038555A2/en
Publication of WO1996038555A3 publication Critical patent/WO1996038555A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • C07K14/43545—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes from Caenorhabditis
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

UNC-53 protein of C. elegans or its functional equivalent is identified as a signal transducer/integrator involved in controlling the rate and directionality of cell migration and/or cell shape. Nucleic acid sequences encoding UNC-53 protein or its functional equivalent, such as genomic or cDNA are used to transfect C. elegans or mammalian cell lines useful for identifying inhibitors or enhancers of the UNC-53 protein. Any of the inhibitors or enhancers identified or the UNC-53 protein itself or sequences encoding UNC-53 protein can be used in the preparation of medicament for treatment of neurological conditions such as Alzheimer's or Huntingdon's disease, peripheral neuropathies for inhibition of metastasis.
PCT/EP1996/002311 1995-05-31 1996-05-31 Unc-53 from c. elegans and its uses in testing compounds involved in the control fo cell behaviour and pharmaceutical compositions Ceased WO1996038555A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
DE69636388T DE69636388D1 (en) 1995-05-31 1996-05-31 LINC-53 FROM C. ELEGANS AND ITS USES
EP96918643A EP0832222B1 (en) 1995-05-31 1996-05-31 Linc-53 from c. elegans and its uses in listing compounds involved in the control of cell behaviour and pharmaceutical compositions
AU61234/96A AU6123496A (en) 1995-05-31 1996-05-31 Processes for the identification of compounds which control cell behaviour, the compounds identified and pharmaceutical compositions containing them and their use in the control of cell behaviour

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9510944.3A GB9510944D0 (en) 1995-05-31 1995-05-31 Assays and processes for the identification of compounds which control cell behaviour,the compounds identified and their use in the control of cell behaviour
GB9510944.3 1995-05-31

Publications (2)

Publication Number Publication Date
WO1996038555A2 WO1996038555A2 (en) 1996-12-05
WO1996038555A3 true WO1996038555A3 (en) 1997-01-30

Family

ID=10775250

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002311 Ceased WO1996038555A2 (en) 1995-05-31 1996-05-31 Unc-53 from c. elegans and its uses in testing compounds involved in the control fo cell behaviour and pharmaceutical compositions

Country Status (6)

Country Link
EP (1) EP0832222B1 (en)
AT (1) ATE334198T1 (en)
AU (1) AU6123496A (en)
DE (1) DE69636388D1 (en)
GB (1) GB9510944D0 (en)
WO (1) WO1996038555A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997046552A1 (en) * 1996-05-31 1997-12-11 Janssen Pharmaceutica N.V. 1-(1h-pyrrol-2-ylmethyl)-2-piperidone as cell migration inhibitor
GB9625283D0 (en) * 1996-12-04 1997-01-22 Janssen Pharmaceutica Nv Vertebrate homologues of unc-53 protein of c.elegans or functional eqivalents thereof and cdna sequences coding for said homologue
GB9811962D0 (en) * 1998-06-03 1998-07-29 Janssen Pharmaceutica Nv Vertebrate homologue of UNC-53 protein of C.elegans
US7005423B1 (en) 1999-07-02 2006-02-28 Devgen Nv Characterization of gene function using double stranded RNA inhibition
GB9827152D0 (en) * 1998-07-03 1999-02-03 Devgen Nv Characterisation of gene function using double stranded rna inhibition
GB9826890D0 (en) * 1998-12-07 1999-01-27 Devgen Nv Method for screening compounds
US6723557B1 (en) 1999-01-06 2004-04-20 California Institute Of Technology Caenorhabditis elegans LOV-1 gene
DE19908423A1 (en) * 1999-02-26 2000-08-31 Deutsches Krebsforsch Protein involved in the development of the CNS
GB9906018D0 (en) * 1999-03-16 1999-05-12 Devgen Nv Expression of DNA or proteins in C.elegans
US6787125B1 (en) 1999-04-15 2004-09-07 Devgen Nv Compound screening method
US6540996B1 (en) 1999-04-15 2003-04-01 Devgen Nv Compound screening methods
GB2351151B (en) * 1999-04-15 2001-07-25 Devgen Nv Compound Screening Method in Nematode Worms
DE10042609A1 (en) * 2000-08-30 2002-03-28 Deutsches Krebsforsch Use of T-proteins for the differential characterization and therapy of injuries and tumors of the nervous system
CN111363732B (en) * 2020-03-12 2023-05-23 卡柔恩赛生物技术湖北有限公司 Transaminase mutant from aspergillus terreus NIH2624 and application thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EMBL Database Entry CEF45E10 Accession number Z47810; 26 January 1995 *
HEKIMI S ET AL: "Axonal guidance defects in a Caenorhabditis elegans mutant reveal cell-extrinsic determinants of neuronal morphology.", JOURNAL OF NEUROSCIENCE 13 (10). 1993. 4254-4271. ISSN: 0270-6474, XP000612286 *
R. WILSON ET AL.: "2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans", NATURE, vol. 368, no. 6466, 3 April 1994 (1994-04-03), LONDON GB, pages 32 - 38 *

Also Published As

Publication number Publication date
DE69636388D1 (en) 2006-09-07
ATE334198T1 (en) 2006-08-15
EP0832222A2 (en) 1998-04-01
GB9510944D0 (en) 1995-07-26
WO1996038555A2 (en) 1996-12-05
AU6123496A (en) 1996-12-18
EP0832222B1 (en) 2006-07-26

Similar Documents

Publication Publication Date Title
AU6123496A (en) Processes for the identification of compounds which control cell behaviour, the compounds identified and pharmaceutical compositions containing them and their use in the control of cell behaviour
Okazaki et al. Molecular mechanism of the reversibility of hepatic fibrosis: with special reference to the role of matrix metalloproteinases
WO2000050639A3 (en) Gene sequence variations with utility in determining the treatment of disease
NZ335945A (en) Presenilin proteins and genetic sequences that are related to Alzheimer's disease
WO2000031235A3 (en) Nucleotide and protein sequences of nogo genes and methods based thereon
ATE418563T1 (en) NIK PROTEINS, NUCLEIC ACID AND METHODS
WO1999057322A3 (en) Genotyping the human udp-glucuronosyltransferase 1 (ugt1) gene
EP1449849A3 (en) Protease-resistant thrombomodulin analog
WO2001034768A3 (en) 15 human secreted proteins
HUP9802961A2 (en) Binding partners for cyclin-dependent kinase-inhibitors, use thereof for exploring of inhibitors of deseases, for diagnostic and therapy
CA2083377A1 (en) Compositions and methods for modulating rna activity through modification of the 5' cap structure of rna
ATE188257T1 (en) USE OF REAGENTS DERIVED FROM THE HUMAN METASTASIS SUPPRESSION GENE KAI1 IN DIAGNOSTIC AND GENETIC THERAPEUTIC PROCEDURES
WO2001046394A3 (en) Mammalian protein phosphatases
WO2003016563A3 (en) Novel molecular target for neurotoxicity
DE3583220D1 (en) USE OF DIPEPTIDE DERIVATIVES FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE TREATMENT OF AMYOTROPHER'S LATERAL Sclerosis.
WO2000063230A3 (en) 49 human secreted proteins
WO1994000572A3 (en) Gene for ataxia-telangiectasia complementation group d (atdc)
WO2003076658A3 (en) A susceptibility gene for late-onset idiopathic parkinson's disease
WO2001064876A3 (en) Human schizophrenia gene
AU737504B2 (en) Novel calpaines, their preparation and use
Sakiyama et al. Control of the synthesis of T4 phage deoxynucleotide kinase messenger ribonucleic acid in vivo
WO1998024810A3 (en) Vertebrate homologues of unc-53 protein of c. elegans
WO2002000872A3 (en) Compositions and methods for treating or detecting degenerative diseases of the motor neurons
Tsuda et al. Detection of a new mutant α-1-antichymotrypsin in patients with occlusive-cerebrovascular disease
FR2694001B1 (en) Process for the synthesis of chloracetic acid in which the hydrochloric acid is purified by product.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1996918643

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996918643

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWG Wipo information: grant in national office

Ref document number: 1996918643

Country of ref document: EP